Evidence map›Paper›PMID 40862281›Full record

ArticleJournal of clinical and translational hepatology2025

Adrenomedullin as an Immunomodulator of CD14

Francesca Maria Trovato, Florent Artru, Roosey Sheth, Rima Abdalla, Joseph Wilson, Anna Broderick, John Smith, Stephen Atkinson, Mark J McPhail

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and translational hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Francesca Maria TrovatoSchool of Immunology and Microbial Sciences, King's College London, London, UK.ORCID https://orcid.org/0000-0002-8048-1646
Florent ArtruSchool of Immunology and Microbial Sciences, King's College London, London, UK.
Roosey ShethSchool of Immunology and Microbial Sciences, King's College London, London, UK.
Rima AbdallaInstitute of Liver Studies, King's College Hospital, Denmark Hill, London, UK.
Joseph WilsonInstitute of Liver Studies, King's College Hospital, Denmark Hill, London, UK.
Anna BroderickAnaesthetics, Critical Care, Emergency Medicine and Trauma Research Delivery Unit, King's College Hospital, Denmark Hill, London, UK.
John SmithAnaesthetics, Critical Care, Emergency Medicine and Trauma Research Delivery Unit, King's College Hospital, Denmark Hill, London, UK.
Stephen AtkinsonSection of Hepatology and Gastroenterology, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College, London, UK.
Mark J McPhailSchool of Immunology and Microbial Sciences, King's College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Liver failure syndromes are characterised by a dysregulated immune response leading to immune paralysis. Adrenomedullin (ADM) is a potent vasodilator and immunoregulator. This study aimed to explore the role of ADM in liver failure, hypothesising that there is a detrimental imbalance between ADM and adrenomedullin binding protein (AMBP)1 that promotes a switch of monocytes/macrophages towards a pro-restorative phenotype and function. Methods: Consecutive patients with acute liver failure (ALF), acute-on-chronic liver failure (ACLF), and decompensated cirrhosis, as well as healthy controls (HC) were included between April 2020 and June 2024. Peripheral blood mononuclear cells/monocytes were isolated and used for RNA sequencing and cell culture. ADM and AMBP1 were measured by enzyme-linked immunosorbent assay. Results: Fifty-four patients with ALF, 25 with ACLF, 9 with decompensated cirrhosis, and 16 with HC were included. ADM expression in isolated monocytes was increased in ALF (log fold change = 5.88, Conclusions: ADM is increased in liver failure, whereas AMBP1 is reduced. ADM affects monocyte function, increasing Mer Tyrosine Kinase and promoting a pro-restorative, anti-inflammatory phenotype.

Indexed as

Acute liver failureAcute-on-chronic liver failureAdrenomedullinAdrenomedullin binding protein-1MerTKMer tyrosine kinaseMonocyte

Identifiers

PMID40862281
PMCPMC12375822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.